文献速递冠心病心力衰竭与心肌病

稳态趋化因子与急性冠脉综合征患者预后

Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该研究在1146例急性冠脉综合征患者入院次日晨间检测血清CCL19与CCL21水平,并校正GRACE评分、左室射血分数、pro-BNP、肌钙蛋白I及C反应蛋白,发现入院时CCL21处于第四四分位者长期MACE与心肌梗死风险显著升高,CCL21高水平亦独立关联短期MACE与心血管死亡,高CCL19则与心力衰竭发生相关。

要点

  • ACS入院时CCL21第四四分位水平与长期MACE及心肌梗死风险独立相关。
  • 入院时高CCL21水平独立关联3个月随访期MACE与心血管死亡。
  • 入院时高CCL19水平与心力衰竭发生相关。

核心结论

  • CCL21水平独立关联ACS后结局,是值得进一步研究的有前景生物标志物。

研究设计与样本

  • 研究纳入1146例ACS患者,于入院后第一个晨间采集血清检测CCL19与CCL21水平,并校正GRACE评分、左室射血分数、pro-BNP、肌钙蛋白I及C反应蛋白。

主要发现

  • 入院时CCL21处于第四四分位者,长期(中位98个月)MACE与心肌梗死风险在完全校正多变量模型中显著升高。
  • 入院时高CCL21水平在短期(3个月)随访中独立关联MACE与心血管死亡。
  • 入院时高CCL19水平与心力衰竭发生相关。

临床怎么用

  • CCL21有望作为ACS患者风险分层与预后评估的候选生物标志物,但尚需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The chemokines CCL19 and CCL21 are up-regulated in atherosclerotic disease and heart failure, and increased circulating levels are found in unstable versus stable coronary artery disease. OBJECTIVES: The purpose of this study was to evaluate the prognostic value of CCL19 and CCL21 in acute coronary syndrome (ACS). METHODS: CCL19 and CCL21 levels were analyzed in serum obtained from ACS patients (n = 1,146) on the first morning after hospital admission. Adjustments were made for GRACE (Global Registry of Acute Coronary Events) score, left ventricular ejection fraction, pro-B-type natriuretic peptide, troponin I, and C-reactive protein levels. RESULTS: The major findings were: 1) those having fourth quartile levels of CCL21 on admission of ACS had a significantly higher long-term (median 98 months) risk of major adverse cardiovascular events (MACE) and myocardial infarction in fully adjusted multivariable models; 2) high CCL21 levels at admission were also independently associated with MACE and cardiovascular mortality during short-time (3 months) follow-up; and 3) high CCL19 levels at admission were associated with the development of heart failure. CONCLUSIONS: CCL21 levels are independently associated with outcome after ACS and should be further investigated as a promising biomarker in these patients.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Caidahl K, Hartford M, Ravn-Fischer A, et al. Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2019. PMID: 31395128. doi:10.1016/j.jacc.2019.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。